CELLULAR DYNAMICS INTERNATIONAL SIGNS AGREEMENT WITH NANION TECHNOLOGIES TO ENHANCE MUTUAL OFFERINGS FOR RESEARCHERS
Madison, Wisconsin, September 20, 2017— Cellular Dynamics International (CDI), a FUJIFILM company, the leading developer and manufacturer of differentiated cells derived from human induced pluripotent stem cells (iPSCs), and Nanion Technologies GmbH (Nanion), a leading provider of instrumentation for ion channel drug discovery and screening, announced today that they have entered into a joint marketing agreement. The mutual partnership will offer research customers access to CDI’s suite of human iPSC-derived tissue cells paired with the high performance instrument platforms from Nanion to drive functional readouts on human cell models.
Currently developed as a one year program, participating research customers will receive Nanion’s CardioExcyte 96 instrument in conjunction with a supply and participation agreement with CDI. Under the program, CDI will provide iPSC-derived differentiated cells, Nanion will provide on-site training for CardioExcyte 96 use. At the end of the year, the customer’s contract can be renewed or the CardioExcyte 96 instrument can be purchased at a depreciated market value. Both companies expect to continue to develop and expand their suite of co-developed applications offered under this program.
“Cutting edge techniques can often be out of reach for many investigators. This program increases testing equipment availability while enabling researchers to take full advantage of the benefits provided by CDI’s human iPSC-derived tissue specific cells,” said Dr. Bruce Novich, Division President-CNBD for FUJIFILM Holdings America Corporation and Division President – Life Sciences for CDI.” The net result across the research community will be greater access to better tools with more rapid generation of impactful results.”
“The CardioExcyte 96 measures electrical activity as well as cell movement and changes in morphology. This is well suited for basic research, toxicity testing, and therapeutic development across a suite of endpoints including, but not limited to cardiac function, cell attachment, spreading and proliferation, quantification of cell behavior in a confluent layer, with regard to barrier function, and quality of cell-cell and cell-substrate adhesions,” stated Niels Fertig, Founder and CEO for Nanion Technologies GmbH. “CDI produces many cell types central to these endpoints and we are excited to launch this combined effort that bundles and increases access to these technologies.”
For more information please visit CDI at https://cellulardynamics.com/ and Nanion at http://www.nanion.de/.
Cellular Dynamics International (CDI), a FUJIFILM company, is a leading developer and supplier of human cells used in drug discovery, toxicity testing, and regenerative medicine applications. Leveraging technology that can be used to create induced pluripotent stem cells (iPSCs) and differentiated tissue-specific cells from any individual, CDI is committed to advancing life science research and transforming the therapeutic development process in order to fundamentally improve human health. The company’s inventoried iCell® products and donor-specific MyCell® Products are available in the quantity, quality, purity, and reproducibility required for drug and cell therapy development. For more information please visit
FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2017, the company had global revenues of $21.5 billion, at an exchange rate of 108 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.
Nanion Technologies is a leading provider of instrumentation for ion channel drug discovery and screening. Founded in 2002, Nanion has grown over the last 15 years to a company with over 100 employees worldwide. With headquarters in Munich, Germany, Nanion has subsidiaries in the USA, Denmark, Japan and China, as well as distribution partners in seven other countries. The Nanion team has developed and successfully established four generations of automated patch clamp instruments for sophisticated and high throughput applications in ion channel research and drug discovery. www.nanion.de
All product and company names herein may be trademarks of their registered owners.
Dr. Niels Fertig
Nanion Technologies GmbH
+49 89 219095 072